Rodolfo Do Couto Maia

Rodolfo Do Couto Maia

Auto-generated profile, based on publicly available information

Rodolfo Do Couto Maia

Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®, http://www.lassbio.icb.ufrj.br)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2018 in MedChemComm
Verified
Journal Article
Closed access
PDF file
PSPaula Nogueira da Silva
Paula Nogueira da Silva
RCRaissa Alves da Conceição
Raissa Alves da Conceição
RMRodolfo Do Couto Maia
Rodolfo Do Couto Maia
Maria Letícia de Castro BarbosaMaria Letícia de Castro Barbosa
Maria Letícia de Castro Barbosa
Novel SGLT-2 selective inhibitors, an innovative therapeutic approach for glycemia control in diabetic patients.

1 September 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RMRodolfo C. Maia
Rodolfo C. Maia
LSLeandro L. Silva
Leandro L. Silva
EMEduardo F. Mazzeu
Eduardo F. Mazzeu
MFMilla M. Fumian
Milla M. Fumian
CRClaudia Moraes de Rezende
Claudia Moraes de Rezende
Carlos FragaCarlos Fraga
Carlos Fraga

2 November 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
RMRodolfo C. Maia
Rodolfo C. Maia
EBEliezer J Barreiro
Eliezer J Barreiro
A SARS-CoV-2 main protease (MPRO) inhibitor was discovered employing molecular docking and a fragment-based pharmacophore model as virtual screening strategies.

6 June 2026 in Chemical Papers
Verified
Journal Article
Open access
HFHarold H. Fokoue
Harold H. Fokoue
Lucas Silva FrancoLucas Silva Franco
Lucas Silva Franco
RMRodolfo C. Maia
Rodolfo C. Maia
EBEliezer J Barreiro
Eliezer J Barreiro
CSCarlos Mauricio Sant´Anna
Carlos Mauricio Sant´Anna